


INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No.	07691.0009	Serial No.	09/580,491				
Applicant	Kurt HERTOGS et al.						
Filing Date	May 30, 2000	Group	1631				




U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	Translation Yes or No
NG		WO 97/27480	07/31/97	PCT	C12Q	1/68	Yes

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
NG	Angarano et al., "Genotype and Phenotype Resistance: An Overview," <i>Journal of Biological Regulators and Homeostatic Agents</i> , 14, pp. 11-14 (2000).
	Anton et al., "Comparative Patterns of HIV-1 Genotypic and Phenotypic Resistance Profiles in Gut and Plasma," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 86, Vol. 4, Supp. 1 (1999).
	Bethune et al., "Does Natural or Acquired Resistance to Reverse Transcriptase and Protease Inhibitors, Observed in HIV-1 Groups M (Subtypes A-H) and O, Differ from Subtype B," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 49, Vol. 4, Supp. 1 (1999).
	Bloor et al., "Lamivudine-Resistant HIV-1 Clinical Isolates Lacking the Met184Val Mutation have Novel Polymorphisms in RT," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 25, Vol. 4, Supp. 1 (1999).
	Casado et al., "Rate of Non-nucleoside Reverse Transcriptase Inhibitor Resistance Among Patients Failing a Nevirapine Plus Protease Inhibitor-Containing Regimen," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 114, Vol. 1, Supp. 1 (1999).
	Calvez, V., "Resistance to Antiretroviral Drugs," <i>Antiviral Therapy</i> , 3(4), pp. 5-7 (1998).
	Chen et al., "Drug Resistance Mutations as Predictors of Phenotypic Zidovudine Resistance in HIV-1 infection," <i>AIDS</i> , 11(12), pp. 1528-1529 (1997).
	Condra et al., "Genotypic or Phenotypic Susceptibility Testing May not Predict Clinical Responses to Indinavir," <i>Antiviral Therapy</i> , 1 st International Workshop HIV Resistant Treatment Strategies and Eradication, Abstracts 47, pp. 48-49 (1997).
NG	Condra, Jon H., "Resisting Resistance: Maximizing the Durability of Antiretroviral Therapy," <i>Annals of Internal Medicine</i> , 128 (11) pp. 951-955 (1998).

NG	D'Aquila, R.T., "HIV-1 Chemotherapy and Drug Resistance," <i>Clin. Diagnost. Virol</i> , 3, 299-3166 (1995).
	Deeks et al., "Novel Four-Drug Salvage Treatment Regimens After Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor--Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic Outcome," <i>The Journal of Infectious Disease</i> , 179, pp. 1375-1381(1999).
	Deeks et al., 2 nd Int'l Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy Abstr. 53 (1998).
	Eastman et al., "Comparison of Selective Polymerase Chain Reaction Primers and Differential Probe Hybridization of Polymerase Chain Reaction Products for Determination of Relative Amounts of Codon 215 Mutant and Wild-Type HIV-1 Populations," <i>J. Acq. Imm. Def. Syndr. Human Retrovirol.</i> , 9, 264-273 (1995).
	Eastman et al., "Nonisotopic Hybridization Assay for Determination of Relative Amounts of Genotypic Human Immunodeficiency Virus Type 1 Zidovudine Resistance," <i>J. Clin. Micro.</i> , 33, 2777-2780 (1995).
	Esté et al., "HIV Phenotype & Genotype Data Highlights," 2 nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy (1998).
	Fodor et al., "Multiplexed Biochemical Assays with Biological Chips," <i>Nature</i> , 364, 555-556 (1993).
	Gianotti et al., "Study on Mutations and Antiretroviral Therapy (SMART): Preliminary Results," <i>Antiviral Therapy</i> , 4(3), pp. 65-69 (1999).
	Gianotti et al., "The Rationale for a Study on HIV-1 Reverse Transcriptase Mutations and Outcome of Antiretroviral Therapy with Two Nucleoside Analogs," <i>Journal of Biological Regulators and Homeostatic Agents</i> , pp. 158-162 (1999).
	Gingeras et al., "Use of Self-Sustained Sequence Replication Amplification Reaction to Analyze and Detect Mutations in Zidovudine-Resistant Human Immunodeficiency Virus," <i>The Journal of Infectious Disease</i> , 164, 1066-1074 (1991).
	Hammer et al., "Relationship of Phenotypic and Genotypic Resistance Profiles to Virological Outcome in a Trial of Abacavir, Nelfinavir, Efavirenz and Adefovir Dipivoxil in Patients with Virological Failure Receiving Indinavir," 3 rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 64, Vol. 4, Supp. 1 (1999).
	Harada et al., "Infection of HTLV-III/LAV in HTLV-1-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay," <i>Science</i> , 229, pp. 563-566 (1985).
	Harrigan et al., "Drug Resistance and Short Term Virological Response in Patients Prescribed Multidrug Rescue Therapy," 3 rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 62, Vol. 4, Supp. 1 (1999).
	Hertogs et al., "Comprehensive HIV Drug Resistance Monitoring Using Rapid, High-Throughput Phenotypic and Genotypic Assays with Correlative Data Analysis," Int'l Congress on Drug Therapy in HIV Infection, Abstracts OP3.4, Vol. 12, Supp. 4 (1998).
	Hertogs et al., "A Rapid Method of Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs," <i>Agents Chemother.</i> , 42, 269-276 (1998).
	Hertogs et al., "A Blinded Comparative Analysis of Two Genotyping Service Laboratories: Full Sequence Analysis of HIV-1 Protease and Reverse Transcriptase," 3 rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 87, Vol. 4, Supp. 1(1999).
NG	Hertogs et al., "Common, Rare and New Genotypic and/or Phenotypic HIV-1 Resistance Profiles Observed in Routine Clinical Practice: A Survey of Over 5000 Isolates," 3 rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 108, Vol. 4, Supp 1 (1999).

NG	Hertogs et al., "Testing for HIV-1 Drug Resistance: New Developments and Clinical Implications," <i>Recent Res. Dev. Antimicrob. Agents Chemother.</i> , 3(Pt. 1), 83-104. (1999)
	Hertogs et al., "A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V," <i>Antimicrob. Agents Chemother.</i> , 44(3), 568-573 (2000).
	Hirsch et al., "Antiretroviral Drug Resistance Testing in Adults With HIV Infection," <i>JAMA</i> , 279(24), pp. 1984-1991 (1998).
	Holodniy et al., "Determination of Human Immunodeficiency Virus RNA in Plasma and Cellular Viral DNA Genotypic Zidovudine Resistance and Viral Load During Zidovudine-Didanosine Combination Therapy," <i>Journal of Virology</i> , 69, 3510-3516 (1995).
	Jopour et al., "Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 Isolates," <i>Antimicrob. Agents Chemother.</i> , 37, 1095-1101 (1993).
	Kellam et al., "Recombinant Virus Assay: A Rapid, Phenotypic Assay for Assessment of Drug Susceptibility of Human Immunodeficiency Virus Type 1 Isolates," <i>Antimicrobial Agents and Chemotherapy</i> , pp. 23-30 (1994).
	Kempf et al., "Analysis of Virological Response to ABT-378/Ritonavir Therapy in Protease Inhibitor-Experienced Patients with Respect to Baseline Viral Phenotype and Genotype," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 8, Vo. 4, Supp. 1 (1999).
	Kemp et al., "Analysis of 5000 HIV-1 Clinical Samples Reveals Complex Non-nucleoside RT Inhibitor Resistance Patterns," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 26, Vol. 4, Supp. 1 (1999).
	Kuritzkes, Daniel R., "HIV Resistance to Current Therapies," <i>Antiviral Therapy</i> , 2(3), pp. 61-67 (1997).
	Kusimi et al., "Human Immunodeficiency Virus Type 1 Envelope Gene Structure and Diversity In Vivo and after Cultivation In Vivo," <i>J. Virol.</i> , 66, 875-885 (1992).
	Larder et al., "A Complete Survey, in Over 1,500 Clinical HIV-1 Isolates, of Phenotypic and Genotypic Protease Inhibitor Resistance Profiles (Including Gag Cleavage Site Sequences) and Their Relation to Therapy History," <u>Int'l Congress on Drug Therapy in HIV Infection, Abstracts OP3.5</u> , Vol. 12, Supp. 4 (1998).
	Larder et al., "A Family of Insertion Mutations Between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance," <i>Antimicrob. Agents Chemother.</i> , 43(8), 1961-1967 (1999).
	Larder et al., "Tipranavir is Active Against a Large Selection of Highly Protease Inhibitor-Resistant HIV-1 Clinical Samples," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 5, Vol. 4, Supp. 1 (1999).
	Larder et al., "HIV with Reduced Sensivity to Zidovudine (AZT) Isolated During Prolonged Therapy," <i>Science</i> , 243, 1731-1734 (1989).
	Larder, et al., "Predicting HIV-1 Phenotypic Resistance from Genotype Using a Large Phenotype-Genotype Relational Database," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 59, Vol. 4, Supp. 1 (1999).
	Larder et al., "Zidovudine Resistance Predicted by Direct Detection of Mutations in DNA from HIV-Infected Lymphocytes," <i>AIDS</i> , 5, 137-144 (1991).
NG	Leigh-Brown et al., "Associations Between Amino Acids in the Evolution of HIV Type 1 Protease Sequences Under Indinavir Therapy," <i>AIDS Research and Human Retroviruses</i> , 15(3), pp. 247-253 (1999).

Ng	Lennerstrand et al., "Mechanism of Zidovudine and Stavudine Resistance for HIV-1 RT with Amino Acid Insertions Between Codons 68 and 70," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 32, Vol. 4, Supp. 1 (1999).
	Leriche-Guerin et al., "Correlation Between Antiretroviral Resistance Mutations, Biological Parameters, and Clinical Evolution in Zidovudine-Treated Patients Infected with Human Immunodeficiency Virus Type 1," <i>Eur. J. Clin. Microbiol. Infect. Dis.</i> , 16, pp. 660-668 (1997).
	Lorenzi et al., "Impact of Drug Resistance Mutations on Virologic Response to Salvage Therapy," <i>AIDS</i> , 13, pp. F17-F21 (1999).
	Miller et al., "Phenotypic Susceptibility to Adefovir Dipivoxil in Clinical Samples with Defined RT Genotypic Resistance Patterns," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 40, Vol. 4, Supp. 1 (1999).
	Miller et al., "Correlates of Resistance to Individual Nucleoside Drugs in Patients who Have Never Taken Them," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 41, Vol. 4, Supp. 1 (1999).
	Miller et al., "Prevalence of Baseline Drug Resistance Mutations in Primary HIV Infection Patients from the QUEST Study," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 141, Vol. 4, Supp. 1 (1999).
	Moyle, G., "Current Knowledge of HIV-1 Reverse Transcriptase Mutations Selected During Nucleoside Analogue Therapy: The Potential to Use Resistance Data to Guide Clinical Decisions," <i>Journal of Antimicrobial Chemotherapy</i> , 40, pp. 765-777 (1997).
	Pauwels et al., <u>2nd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Lake Maggiore, Italy, Abstr. 51 (1998).
	Pauwels et al., "Rapid and Automated Tetrazolium-based Colorimetric Assay for the Detection of Anti-HIV Compounds," <i>J. Virol. Methods</i> , 20, 309-321 (1998).
	Perez-Olmeda et al., "Usefulness of Genotypic Analysis of Resistance to Nucleoside Analogues in the Clinical Setting," <i>Eur. J. Clin. Microbiol. Infect. Dis.</i> , 18, pp. 448-449 (1999).
	Piketty et al., "Efficacy of a Five-Drug Combination Including Ritonavir, Saquinavir and Efavirenz in Patients Who Failed on a Conventional Triple-Drug Regimen: Phenotypic Resistance to Protease Inhibitors Predicts Outcome of Therapy," <i>AIDS</i> , 13, pp. F71-F77 (1999).
	Ren et al., "Crystal Structures of HIV-1 RT Inhibitor Complexes: 'Second Generation' NNRTIs, Efavirenz and S-1153 (AG1549), and NNRTI- and NRTI-resistant Mutant Forms," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 20, Vol. 4, Supp. 1 (1999).
	Richman et al., "Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction," <i>The Journal of Infectious Disease</i> , 164, 1075-1081 (1991).
	Schapiro et al., "Clinical Cross-Resistance Between the HIV-1 Protease Inhibitors Saquinavir and Indinavir and Correlations with Genotypic Mutations," <i>AIDS</i> , 13, pp. 359-365 (1999).
	Schinazi et al., "Mutations in Retroviral Genes Associated with Drug Resistance," <i>Int. Antiviral News</i> , 5, 129-142 (1997).
	Schmit et al., "Recent Advances in Antiretroviral Therapy and HIV Infection Monitoring," <i>Intervirology</i> , 40, pp. 304-321 (1997).
NLS	Stuyver et al., "Line Probe Assay for Rapid Detection of Drug-Selected Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene," <i>Antimicrob. Agents Chemotherap.</i> , 41, 284-291 (1997).
	Vandamme et al., "Managing Resistance to Anti-HIV Drugs," <i>Drugs</i> , pp. 337-361 (1999).

NK	Vella, S., "Advances in the Virology of HIV Infection and Implications for Clinical Management, <i>Aids Clinical Care</i> , 10(3), pp. 17-19 (1998).
	Vingerhoets et al., "The Accuracy and Reprorucibility of High Throughput Genotypic and Phenotypic HIV-1 Resistance Testing Under EN45001 and CLIA Accreditation Labels," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 77, Vol. 4, Supp. 1 (1999).
	Verbiest et al., "An Epidemiological Prospective Survey Assessing the Prevalence of HIV-1 Drug Resistance in 230 HIV-1-Positive Antiretroviral-Naive Patients from the USA, <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 122, Vol. 4, Supp. 1 (1999).
	Walter et al., "Rapid, Phenotypic HIV-1 Drug Sensitivity Assay for Protease and Reverse Transcriptase Inhibitors," <i>Journal of Clinical Virology</i> , 13, pp. 71-80 (1999).
	Weber et al., "Molecular Mechanics Analysis of Drug-Resistant Mutants of HIV Protease," <i>Protein Engineering</i> , 12(6), pp. 469-474 (1999).
	Wegner et al., "The Potential Role of Resistance Testing and Therapeutic Drug Monitoring in the Optimization of Antiretroviral Drug Therapy," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 112, Vol. 1. Supp. 1 (1999).
	Wegner et al., "High Frequency of Antiretroviral Drug Resistance in HIV-1 From Recently Infected Therapy-Naive Individuals," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 119, Vol. 4, Supp. 1 (1999).
	Winters et al., "Human Immunodeficiency Virus Type 1 Reverse Transcriptase Genotype and Drug Susceptibility Changes in Infected Individuals Receiving Dideoxyinosine Monotherapy for 1 to 2 Years," <i>Antimicrohbial Agents and Chemotherapy</i> , pp. 757-762 (1997).
	Yahl et al., "Mutation Patterns of the Reverse Transcriptase and Protease Genes in Human Immunodeficiency Virus Type 1-Infected Patients Undergoing Combination Therapy: Survey of 787 Sequences," <i>Journal of Clinical Microbiology</i> , pp. 4099-4106 (1999).
	Zolopa et al., "A Comparision of Phenotypic, Genotypic and Clinical/Treatment History Predictors of Virological Response to Saquinavir/Ritonavir Salvage Therapy in a Clinic-based Cohort," <u>3rd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</u> , Abstract 68, Vol. 4, Supp. 1, 1997).
NK	Zolopa et al., "HIV-1 Genotypic Resistance Patterns Predict Response to Saquinavir-Ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy had Failed," <i>Ann Intern Med.</i> , 131, pp. 813-821 (1999).
Examiner <u>Nikolai Galitsky</u>	Date Considered <u>11.30.01</u> <u>04/24/02</u>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449 Patent and Trademark Office - U.S. Department of Commerce	